Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica
Hlavní autoři: Kenealy, Melita, Hertzberg, Mark, Benson, Warwick, Taylor, Kerry, Cunningham, Ilona, Stevenson, Will, Hiwase, Devendra, Eek, Richard, Zantomio, Daniela, Jong, Steve, Wall, Meaghan, Blombery, Piers, Gerber, Tracey, Debrincat, Marlyse, Zannino, Diana, Seymour, John F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442982/
https://ncbi.nlm.nih.gov/pubmed/30545923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201152
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky